

GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS



HLC029D
January 2013

Paul Evers
Project Analyst

ISBN: 0-89336-238-7

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
MARKET ANALYSES AND FORECASTS	2
METHODOLOGY	2
INTENDED AUDIENCE	2
INFORMATION SOURCES	2
ANALYST CREDENTIALS	2
RELATED REPORTS	3
BCC ONLINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 SUMMARY	5
THE DIABETES MARKET	5
LEADING COMPANIES	5
<i>SUMMARY TABLE DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017 (\$ BILLIONS)</i>	6
<i>SUMMARY FIGURE DIABETES MARKET EVOLUTION BY REGION, 2011-2017 (\$ BILLIONS)</i>	6
CHAPTER 3 OVERVIEW	8
DIABETES BASICS	8
STRUCTURE OF THE DIABETES MARKET	8
DRIVERS FOR GROWTH	8
RISING PREVALENCE	8
<i>TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017 (CASES IN MILLIONS)</i>	8
NEW TECHNOLOGY	9
RATE OF MARKET GROWTH	10
CURRENT TREATMENT OF DIABETES	10
INSULIN	10
Insulin Administration Devices	10
ORAL ANTIDIABETIC DRUGS	11
MONITORING DEVICES FOR DIABETES	11
<i>TABLE 2 TOTAL DIABETES MARKET IN 2012 (\$ BILLIONS)</i>	11
REGIONAL SEGMENTATION	11
<i>TABLE 3 ADULT DIABETES MARKET BY REGION (MILLIONS/%)</i>	12
MARKET GROWTH	12
THE DIABETES INDUSTRY	12
PHARMACEUTICAL COMPANIES	12
MEDICAL DEVICE COMPANIES	13
CHAPTER 4 PRODUCTS AND SUPPLIERS	15
INSULIN	15
HISTORY	15
Bovine and Porcine Insulin	16

TOPIC	PAGE NO.
Humanized Insulin	16
COMPANIES SUPPLYING INSULIN	17
Eli Lilly	17
Sanofi	17
Novo Nordisk	17
Some Other Suppliers	17
Wockhardt Limited: India	17
BioconB: India	18
Shreya Life Sciences: India	18
Diosynth: the Netherlands	18
<i>TABLE 4 MAJOR BRANDS OF INSULIN</i>	18
INSULIN DELIVERY	19
SYRINGES	19
INSULIN SYRINGE MANUFACTURERS	19
Becton Dickinson	19
Owen Mumford	20
Terumo	20
B. Braun	20
PENS	20
<i>TABLE 5 INSULIN PENS</i>	21
MANUFACTURERS OF INSULIN PENS	21
Novo Nordisk	21
Owen Mumford	22
Other Makers	22
INJECTORS	22
INJECTOR MANUFACTURERS	23
Activa Brand Products	23
Antares Pharma	23
Bioject	23
MediCool Inc.	23
Owen Mumford	24
Palco Labs Inc.	24
Rosch AG Medizintechnik	24
INSULIN PUMPS	24
What Is an Insulin Pump?	24
The Infusion Set	25
Candidates for Pump Therapy	25
COMPANIES SUPPLYING INSULIN PUMPS	26
Animas Corp.	26
Sooil Development Co.	27
Medtronic MiniMed	27
Nipro Diabetes Systems	27
Roche Insulin Delivery Systems	27
Insulet	27
Tandem Diabetes Care	28
<i>TABLE 6 INSULIN PUMPS</i>	28
Problems with Pumps-or Users?	28

TOPIC	PAGE NO.
ORAL HYPOGLYCEMIC DRUGS	29
SULFONYLUREAS	29
<i>TABLE 7 SULFONYLUREAS</i>	29
BIGUANIDES	30
ALPHA-GLUCOSIDASE INHIBITOR	30
GLITAZONES	30
PRANDIAL GLUCOSE REGULATORS	30
GLP-1 ANALOGS; ALSO KNOWN AS INCRETIN MIMETICS	31
AMYLIN MIMETIC	31
<i>TABLE 8 ORAL HYPOGLYCEMICS</i>	32
DIAGNOSIS AND MONITORING	32
THE ROLE OF SELF-MONITORING	32
SMBG Frequency	33
BLOOD GLUCOSE MONITORING DEVICES: SUPPLIERS AND PRODUCTS	33
Lancets	34
<i>TABLE 9 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS</i>	34
BLOOD-SAMPLING DEVICES	34
Bayer Diagnostics	34
Becton Dickinson	35
Cell Robotics	35
LifeScan	35
Roche Diagnostics	35
BLOOD GLUCOSE MONITORS	35
77 Elektronika Kft	35
Abbott Laboratories	36
Acon Laboratories Inc.	36
AgaMatrix Inc.	36
Apex Biotechnology Corp.	37
Arkray USA	37
Aventir Biotech LLC	37
Bayer Corp.	37
Belbiosens	38
Diagnostic Devices Inc.	38
Eumed Biotechnology Co. Ltd.	38
GlucoPlus Inc.	38
HMD Bio Medical	38
Health & Life Co.	38
HemoCue AB	39
Home Diagnostics Inc.	39
Hypoguard	39
i-SENS Inc.	39
LifeScan Inc.	39
Medtronic	39
Menarini Diagnostics	40
National Diagnostic Products	40
Novabiomedical Corp.	40
Roche	40

TOPIC	PAGE NO.
TaiDoc Technology Corp.	41
US Diagnostics Inc.	41
GLUCOSE METER ACCURACY	41
OTHER TESTING APPROACHES	42
HEMOGLOBIN A1C	42
Hemoglobin A1c Meters	42
Hemoglobin A1c Kits	43
SOFTWARE AIDS TO DIABETES MONITORING	44
AIDA On-Line	44
Bayer Care: Blood Sugar Log	44
Body Sigma	44
Dailyrating	44
DiabetEASE	44
Diabetes Assistant	45
Diabetes Homecare Center	45
Ecivon	45
HealthEngage Diabetes	45
Lifeclinic	46
PlasmaGlucose	46
Symcare	46
CHAPTER 5 NEW DEVELOPMENTS IN DIABETES	48
APPROACHES BASED ON CURRENT TECHNOLOGY	48
NOVEL INSULIN DELIVERY TECHNOLOGY	48
Oral-Lyn	48
Oramed	48
Medingo Micro-Pump Patch	48
Inhaled Insulin	49
Transdermal Approach	49
IMPROVED ORAL ANTIDIABETIC DRUGS	50
Dutogliptin	50
Byetta LAR	50
Lixisenatide	50
NEW DEVELOPMENTS IN GLUCOSE TESTING	51
Continuous Glucose Monitoring (CGM)	51
Reimbursement	52
Noninvasive Monitoring	52
<i>TABLE 10 SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING</i>	55
Integrated Testing	56
ARTIFICIAL PANCREAS	57
Roche	57
Abbott	58
Novo Nordisk/LifeScan	58
Animas	58
RADICAL APPROACHES	59
ALTERNATIVES TO INSULIN	59
IMMUNOTHERAPY	60

TOPIC	PAGE NO.
TRANSPLANTATION	60
CELL AND STEM CELL THERAPIES	61
GENE THERAPY	62
Gene Therapy Approaches for Expressing Insulin	62
Gene Therapy Approaches for Immunomodulation	62
Gene Therapy Approaches for Cell-Based Therapies	62
A NEW AGE OF MOBILITY IN DIABETES MANAGEMENT	63
THE IMPACT OF NEW DEVELOPMENTS ON THE DIABETES MARKET	64
CHAPTER 6 THE GLOBAL DIABETES MARKET	67
MARKET COMPONENTS	67
SIZE	67
<i>TABLE 11 GLOBAL DIABETES MARKET, 2011 (\$ BILLIONS)</i>	67
GROWTH	68
MARKET ANALYSIS BY PRODUCT CATEGORY	68
INSULINS AND INSULIN DELIVERY DEVICES	68
Major Suppliers	69
<i>TABLE 12 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011 (\$ MILLIONS)</i>	69
OTHER ANTIDIABETIC DRUGS	69
Major Suppliers	69
<i>TABLE 13 SALES OF OTHER ANTIDIABETIC DRUGS, 2011 (\$ MILLIONS)</i>	70
INSULIN PUMPS	70
<i>TABLE 14 DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017 (\$ BILLIONS)</i>	71
MONITORING PRODUCTS	71
Major Suppliers	71
<i>TABLE 15 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011 (MILLIONS/%)</i>	71
TRENDS	71
REGIONAL SEGMENTATION	72
<i>TABLE 16 RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017 (CASES IN MILLIONS)</i>	72
NATIONAL MARKETS	72
North America	73
<i>TABLE 17 TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017 (\$ BILLIONS)</i>	73
South and Central America	74
<i>TABLE 18 TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017 (\$ BILLIONS)</i>	74
Europe	74
<i>TABLE 19 MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	75
Asia	75
<i>TABLE 20 MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	75
CHAPTER 7 THE AMERICAN MARKET	77
NORTH AMERICA	77
THE U.S.	77
Vital Statistics	77

TOPIC	PAGE NO.
Health and Health Care	77
THE U.S. PHARMACEUTICAL MARKET	79
The Diabetes Market	79
TABLE 21 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2017 (CASES IN MILLIONS)	79
TABLE 22 U.S.: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	80
TABLE 23 U.S.: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	80
CANADA	80
Vital Statistics	80
Health and Health Care	80
CANADA'S PHARMACEUTICAL MARKET	81
The Diabetes Market	81
TABLE 24 PREVALENCE OF DIABETES IN CANADA, THROUGH 2017 (CASES IN MILLIONS)	82
TABLE 25 CANADA: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	82
TABLE 26 CANADA: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	82
LATIN AMERICA	83
BRAZIL	83
Vital Statistics	83
Health and Health Care	83
BRAZIL'S PHARMACEUTICAL MARKET	84
The Diabetes Market	85
TABLE 27 PREVALENCE OF DIABETES IN BRAZIL, THROUGH 2017 (CASES IN MILLIONS)	85
TABLE 28 BRAZIL: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	85
TABLE 29 BRAZIL: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	85
MEXICO	86
Vital Statistics	86
Health and Health Care	86
MEXICO'S PHARMACEUTICAL MARKET	86
Market Resistors	87
The Diabetes Market	87
TABLE 30 PREVALENCE OF DIABETES IN MEXICO, THROUGH 2017 (CASES IN MILLIONS)	87
TABLE 31 MEXICO: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	88
TABLE 32 MEXICO: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	88
CHAPTER 8 THE ASIAN MARKET	90
CHINA	90
VITAL STATISTICS	90
HEALTH AND HEALTH CARE	90
CHINA'S PHARMACEUTICAL MARKET	91
DOMESTIC INDUSTRY	92
FOREIGN COMPANY INVOLVEMENT	93
IMPORTANCE OF R&D	94
CHALLENGES	94
MARKET TRENDS	94
REGULATORY CHANGES	95
THE DIABETES MARKET	96
TABLE 33 PREVALENCE OF DIABETES IN CHINA, THROUGH 2017 (CASES IN MILLIONS)	96
TABLE 34 CHINA: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	97

TOPIC	PAGE NO.
<i>TABLE 35 CHINA: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	97
INDIA	97
VITAL STATISTICS	97
HEALTH AND HEALTH CARE	97
GROWING AFFLUENCE-CHANGING MEDICAL NEEDS	98
REGULATORY CHANGES	98
INDIA'S PHARMACEUTICAL MARKET	98
DEMOGRAPHIC FACTORS	98
PHARMA INDUSTRY	99
PATENT REFORM	99
THE DIABETES MARKET	100
<i>TABLE 36 PREVALENCE OF DIABETES IN INDIA, THROUGH 2017 (CASES IN MILLIONS)</i>	100
<i>TABLE 37 INDIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)</i>	100
<i>TABLE 38 INDIA: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	101
JAPAN	101
VITAL STATISTICS	101
HEALTH AND HEALTH CARE	101
JAPAN'S PHARMACEUTICAL MARKET	102
<i>TABLE 39 TOP SIX JAPANESE PHARMA COMPANIES, 2010</i>	102
THE DIABETES MARKET	103
<i>TABLE 40 PREVALENCE OF DIABETES IN JAPAN, THROUGH 2017 (CASES IN MILLIONS)</i>	104
<i>TABLE 41 JAPAN: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)</i>	104
<i>TABLE 42 JAPAN: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	104
CHAPTER 9 THE EUROPEAN MARKET	106
FRANCE	106
VITAL STATISTICS	106
HEALTH AND HEALTH CARE	106
PROVISION OF HEALTH CARE	106
FRANCE'S PHARMACEUTICAL MARKET	107
THE DIABETES MARKET	107
<i>TABLE 43 PREVALENCE OF DIABETES IN FRANCE, THROUGH 2017 (CASES IN MILLIONS)</i>	108
<i>TABLE 44 FRANCE: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)</i>	108
<i>TABLE 45 FRANCE: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	108
GERMANY	108
VITAL STATISTICS	109
HEALTH AND HEALTH CARE	109
PROVISION OF HEALTH CARE	109
GERMANY'S PHARMACEUTICAL MARKET	109
PRICE CONTROLS	110
THE DIABETES MARKET	110
<i>TABLE 46 PREVALENCE OF DIABETES IN GERMANY, THROUGH 2017 (CASES IN MILLIONS)</i>	111
<i>TABLE 47 GERMANY: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)</i>	111
<i>TABLE 48 GERMANY: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	111
ITALY	111
VITAL STATISTICS	112
HEALTH AND HEALTH CARE	112

TOPIC	PAGE NO.
PROVISION OF HEALTH CARE	112
ITALY'S PHARMACEUTICAL MARKET	113
IMPLICATIONS FOR RESEARCH	114
THE DIABETES MARKET	114
<i>TABLE 49 PREVALENCE OF DIABETES IN ITALY, THROUGH 2017 (CASES IN MILLIONS)</i>	115
<i>TABLE 50 ITALY: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)</i>	115
<i>TABLE 51 ITALY: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	115
RUSSIA	115
VITAL STATISTICS	115
HEALTH AND HEALTH CARE	116
PROVISION OF HEALTH CARE	116
RUSSIA'S PHARMACEUTICAL MARKET	116
PHARMA 2020	116
THE DIABETES MARKET	117
<i>TABLE 52 PREVALENCE OF DIABETES IN RUSSIA, THROUGH 2017 (CASES IN MILLIONS)</i>	118
<i>TABLE 53 RUSSIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)</i>	118
<i>TABLE 54 RUSSIA: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	118
SPAIN	118
VITAL STATISTICS	119
HEALTH AND HEALTH CARE	119
PROVISION OF HEALTH CARE	119
PHARMACEUTICAL SERVICES	119
SPAIN'S PHARMACEUTICAL MARKET	120
THE DIABETES MARKET	120
<i>TABLE 55 PREVALENCE OF DIABETES IN SPAIN, THROUGH 2017 (CASES IN MILLIONS)</i>	121
<i>TABLE 56 SPAIN: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)</i>	121
<i>TABLE 57 SPAIN: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	121
THE UNITED KINGDOM	122
VITAL STATISTICS	122
HEALTH AND HEALTH CARE	122
PROVISION OF HEALTH CARE	122
Private Sector Involvement	122
PHARMACEUTICALS	123
THE UNITED KINGDOM'S PHARMACEUTICAL MARKET	123
THE DIABETES MARKET	124
<i>TABLE 58 PREVALENCE OF DIABETES IN THE U.K., THROUGH 2017 (CASES IN MILLIONS)</i>	124
<i>TABLE 59 U.K.: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)</i>	125
<i>TABLE 60 U.K.: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)</i>	125
CHAPTER 10 COMPANY PROFILES	127
LEADING COMPANIES	127
ABBOTT LABORATORIES	127
Overview	127
ABBOTT DIABETES CARE, INC.	128
BAYER AG	128
Overview	128
Diabetes Products	129

TOPIC	PAGE NO.
BECTON DICKINSON	129
Overview	129
Diabetes Products	130
BRISTOL-MYERS SQUIBB	130
Overview	130
Problems with Generics	130
Diabetes Products	130
Pipeline	131
ELI LILLY AND CO.	131
Overview	131
Diabetes Products	131
Pipeline	132
GLAXO SMITHKLINE	132
Overview	132
Diabetes Products	132
Pipeline	133
JOHNSON & JOHNSON	133
Overview	133
Diabetes Products	133
Pipeline	134
MEDTRONIC	134
Overview	134
Diabetes Products	135
Pipeline	135
MERCK & CO. LTD.	135
Diabetes	136
SmartCells	136
MERCK KGAA	137
Overview	137
Diabetes Products	137
NOVARTIS INTERNATIONAL AG	138
Overview	138
Diabetes Products	138
Research	138
NOVO NORDISK A/S	139
Overview	139
Diabetes Products	139
Pipeline	140
<i>TABLE 61 NOVO NORDISK DIABETES PRODUCT PIPELINE</i>	141
ROCHE	141
Overview	141
Diabetes Products	142
Blood Glucose Monitoring Systems	142
Diabetes Data Management	143
Insulin Pump Systems	143
Lancet Devices	143
Other	144

TOPIC	PAGE NO.
Pipeline	144
SANOFI	144
Overview	144
Diabetes Products	145
TAKEDA	145
Overview	145
Pipeline	146
<i>TABLE 62 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA</i>	146
OTHER COMPANIES	147
77 ELEKTRONIKA CO., LTD.	147
AGAMATRIX, INC.	147
ANIMAS CORP.	148
BIO-IMPEDANCE GENERAL LTD.	148
DEBIOTECH S.A.	149
INLIGHT SOLUTIONS, INC.	149
LIFESCAN, INC.	150
MANNKIND CORP.	150
A. MENARINI DIAGNOSTICS S.R.L.	151
NIPRO CORP. 3-9-3,	151
OWEN MUMFORD LTD.	152
PALCO LABS, INC.	153
PRODIGY DIABETES CARE LLC	153
TERUMO CORP.	154
TRANSITION THERAPEUTICS INC.	154
CHAPTER 11 APPENDIX I: ABOUT DIABETES	156
BLOOD SUGAR REGULATION	156
INSULIN	156
TYPE 1 DIABETES	157
TYPE 2 DIABETES	157
GESTATIONAL DIABETES	158
OBESITY-RELATED TYPE 2 DIABETES IN CHILDREN	158
MATURE-ONSET DIABETES OF THE YOUNG (MODY)	159
OTHER DIABETIC STATES	159
LATENT AUTOIMMUNE DIABETES (LADA)	159
PREDIABETES	159
DIAGNOSIS	160
GLUCOSE TESTS	160
OFFICIAL CRITERIA	160
DIFFERENTIAL DIAGNOSIS	160
TYPE 1 DIABETES	160
TYPE 2 DIABETES	161
CURRENT TREATMENT	161
TYPE 1 DIABETES	161
TYPE 2 DIABETES	161
Sulfonylureas	162
Biguanides	162

TOPIC	PAGE NO.
Alpha-Glucosidase Inhibitors	162
Glitazones (Thiazolidinediones)	163
Prandial Glucose Regulators	163
Incretin Mimetics	163
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors	163
DIET	163
MONITORING DIABETES	163
BLOOD SUGAR CONTROL	163
THE DIABETES CONTROL AND COMPLICATIONS TRIAL (DCTT)	164
GLYCATED HEMOGLOBIN (HBA1C)	165
FRUCTOSAMINE	166
PREVALENCE OF DIABETES	166
TYPE 1	167
TYPE 2	167
DIABETIC COMPLICATIONS	167
RETINOPATHY	168
NEUROPATHY	168
NEPHROPATHY	169
INCREASED MORTALITY RISK	169
METABOLIC SYNDROME	169
CHAPTER 12 APPENDIX 2: GLOSSARY	172
TABLE 63 GLOSSARY	172

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017 (\$ BILLIONS)	6
TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017 (CASES IN MILLIONS)	8
TABLE 2 TOTAL DIABETES MARKET IN 2012 (\$ BILLIONS)	11
TABLE 3 ADULT DIABETES MARKET BY REGION (MILLIONS/%)	12
TABLE 4 MAJOR BRANDS OF INSULIN	18
TABLE 5 INSULIN PENS	21
TABLE 6 INSULIN PUMPS	28
TABLE 7 SULFONYLUREAS	29
TABLE 8 ORAL HYPOGLYCEMICS	32
TABLE 9 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS	34
TABLE 10 SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING	55
TABLE 11 GLOBAL DIABETES MARKET, 2011 (\$ BILLIONS)	67
TABLE 12 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011 (\$ MILLIONS)	69
TABLE 13 SALES OF OTHER ANTIDIABETIC DRUGS, 2011 (\$ MILLIONS)	70
TABLE 14 DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017 (\$ BILLIONS)	71
TABLE 15 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011 (MILLIONS/%)	71
TABLE 16 RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017 (CASES IN MILLIONS)	72
TABLE 17 TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017 (\$ BILLIONS)	73
TABLE 18 TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017 (\$ BILLIONS)	74
TABLE 19 MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017 (\$ BILLIONS)	75
TABLE 20 MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017 (\$ BILLIONS)	75
TABLE 21 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2017 (CASES IN MILLIONS)	79
TABLE 22 U.S.: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	80
TABLE 23 U.S.: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	80
TABLE 24 PREVALENCE OF DIABETES IN CANADA, THROUGH 2017 (CASES IN MILLIONS)	82
TABLE 25 CANADA: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	82
TABLE 26 CANADA: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	82
TABLE 27 PREVALENCE OF DIABETES IN BRAZIL, THROUGH 2017 (CASES IN MILLIONS)	85
TABLE 28 BRAZIL: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	85
TABLE 29 BRAZIL: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	85
TABLE 30 PREVALENCE OF DIABETES IN MEXICO, THROUGH 2017 (CASES IN MILLIONS)	87
TABLE 31 MEXICO: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	88
TABLE 32 MEXICO: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	88
TABLE 33 PREVALENCE OF DIABETES IN CHINA, THROUGH 2017 (CASES IN MILLIONS)	96
TABLE 34 CHINA: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	97
TABLE 35 CHINA: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	97
TABLE 36 PREVALENCE OF DIABETES IN INDIA, THROUGH 2017 (CASES IN MILLIONS)	100
TABLE 37 INDIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	100
TABLE 38 INDIA: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	101
TABLE 39 TOP SIX JAPANESE PHARMA COMPANIES, 2010	102
TABLE 40 PREVALENCE OF DIABETES IN JAPAN, THROUGH 2017 (CASES IN MILLIONS)	104
TABLE 41 JAPAN: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	104

TABLE HEADING	PAGE NO.
TABLE 42 JAPAN: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	104
TABLE 43 PREVALENCE OF DIABETES IN FRANCE, THROUGH 2017 (CASES IN MILLIONS)	108
TABLE 44 FRANCE: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	108
TABLE 45 FRANCE: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	108
TABLE 46 PREVALENCE OF DIABETES IN GERMANY, THROUGH 2017 (CASES IN MILLIONS)	111
TABLE 47 GERMANY: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	111
TABLE 48 GERMANY: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	111
TABLE 49 PREVALENCE OF DIABETES IN ITALY, THROUGH 2017 (CASES IN MILLIONS)	115
TABLE 50 ITALY: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	115
TABLE 51 ITALY: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	115
TABLE 52 PREVALENCE OF DIABETES IN RUSSIA, THROUGH 2017 (CASES IN MILLIONS)	118
TABLE 53 RUSSIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	118
TABLE 54 RUSSIA: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	118
TABLE 55 PREVALENCE OF DIABETES IN SPAIN, THROUGH 2017 (CASES IN MILLIONS)	121
TABLE 56 SPAIN: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	121
TABLE 57 SPAIN: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	121
TABLE 58 PREVALENCE OF DIABETES IN THE U.K., THROUGH 2017 (CASES IN MILLIONS)	124
TABLE 59 U.K.: DIABETES MEDICATIONS MARKET, THROUGH 2017 (\$ BILLIONS)	125
TABLE 60 U.K.: DIABETES DEVICES MARKET, THROUGH 2017 (\$ BILLIONS)	125
TABLE 61 NOVO NORDISK DIABETES PRODUCT PIPELINE	141
TABLE 62 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA	146
TABLE 63 GLOSSARY	172

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE DIABETES MARKET EVOLUTION BY REGION, 2011-2017 (\$ BILLIONS)	6